Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Ulmert has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Key regulatory elements of the TGFβ–LRRC15 axis predict disease progression and immunotherapy resistance across cancer types

    by Michael Cheng, Claire M. Storey, Mohamed Altai, Julie E. Park, Julie Tran, Smiths S. Lueong, Daniel Thorek, Liqun Mao, Wahed Zedan, Constance Yuen, et al.

    Transforming growth factor-beta (TGFβ) has dual roles in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. Efforts to inhibit TGFβ have been largely unsuccessful due to significant toxicity and indiscriminate immunosuppression. Leucine-rich repeat-containing protein 15 (LRRC15) is a TGFβ-regulated antigen expressed by cancer cells of mesenchymal origin and cancer-associated fibroblasts (CAFs). In preclinical studies, ablation of TGFβ-driven LRRC15+ CAFs enhances effector functions of CD8+ T cells. However, the pathobiological mechanisms associated with TGFβ’s upregulation of LRRC15 expression in cancer cells remain unclear. Using an integrated approach combining functional compound screening with scRNA-seq, we reveal key genomic features regulating TGFβ’s ability to increase LRRC15 expression on cancer cells. Construction of gene regulatory networks converged our analyses on four key genes ( MMP2, SPARC, TGFβR2, and WNT5B ) central to TGFβ-induced LRRC15 pathobiology in cancer cells. Validation of these genes in cell models and their use in predicting immunotherapy responses highlight their potential in refining immunotherapy strategies and personalizing cotreatment options.

  • Open Access

    Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.

  • Open Access

    Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance

    by Claire M. Storey, Mohamed Altai, Katharina Lückerath, Wahed Zedan, Henan Zhu, Lara Breuer, Marija Trajkovic-Arsic, Julie Park, Abbie Hasson, Jens Siveke, et al.

    Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and treatment resistant tumor cells derived from mesenchymal stem cells, with minimal expression observed in non-neoplastic tissues. We have developed a humanized monoclonal antibody, DUNP19, that specifically binds with high affinity to a phylogenetically conserved LRRC15 epitope and is rapidly internalized upon LRRC15 binding. In multiple subcutaneous and orthotopic tumor xenograft mouse models, Lutetium-177 labeled DUNP19 ([177Lu]Lu-DUNP19) enabled non-invasive imaging and molecularly precise radiotherapy to LRRC15-expressing cancer cells and murine cancer-associated fibroblasts, effectively halting tumor progression and prolonging survival with minimal toxicity. Transcriptomic analyses of [177Lu]Lu-DUNP19-treated tumors reveal a loss of pro-tumorigenic mechanisms, including a previously reported TGFβ-induced LRRC15+ signature associated with immunotherapy resistance. In a syngeneic tumor model, administration of [177Lu]Lu-DUNP19 significantly potentiated checkpoint-blockade therapy, yielding durable complete responses. Together, these results demonstrate that radio-theranostic targeting of LRRC15 with DUNP19 is a compelling precision medicine platform for image-guided diagnosis, eradication, and reprogramming of LRRC15+ tumor tissue that drives immuno-resistance and disease aggressiveness in a wide range of currently untreatable malignancies.


  • Open Access

    Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types

    by Claire M. Storey, Michael Cheng, Mohamed Altai, Julie E. Park, Julie Tran, Smiths S. Lueong, Daniel Thorek, Liqun Mao, Wahed Zedan, Constance Yuen, et al.

    Transforming growth factor-beta (TGFβ) has dual roles in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. Efforts to inhibit TGFβ have been largely unsuccessful due to significant toxicity and indiscriminate immunosuppression. Leucine-rich repeat-containing protein 15 (LRRC15) is a TGFβ-regulated antigen expressed by mesenchymal-derived cancer cells and cancer-associated fibroblasts (CAFs). In preclinical studies, ablation of TGFβ-driven LRRC15+ CAFs increased tumor infiltration of CD8+ T cells. However, the underlying pathobiological mechanisms prompting TGFβ’s upregulation of LRRC15 expression are unclear. Using an integrated approach combining functional compound screening with single-cell RNA sequencing, we reveal key genomic features regulating TGFβ’s ability to increase LRRC15 expression on cancer cells. Construction of gene regulatory networks converged our analyses on four key genes— MMP2, SPARC, TGF β R2, and WNT5B —central to TGFβ-induced LRRC15 pathobiology. Validation of these genes in cell models and their use in predicting immunotherapy responses highlight their potential in refining immunotherapy strategies and personalizing co-treatment options.


  • Open Access

    Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance

    by Claire M Storey, Mohamed Altai, Katharina Lückerath, Wahed Zedan, Henan Zhu, Marija Trajkovic-Arsic, Julie Park, Norbert Peekhaus, Jens Siveke, Henrik Lilljebjörn, et al.

    Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. We have developed a humanized monoclonal antibody (mAb), DUNP19, that specifically binds to a phylogenetically conserved LRRC15 epitope and is internalized by target-expressing cancer and stromal cells. In xenograft mouse models, Lutetium-177 labeled DUNP19 ([ 177 Lu]-DUNP19) enables non-invasive imaging and precise radiotherapy to LRRC15-expressing cancer cells and murine cancer-associated fibroblasts (CAFs), halting tumor progression and prolonging survival with minimal toxicity. Transcriptomic analyses of [ 177 Lu]-DUNP19-treated tumors reveal a loss of pro-tumorigenic mechanisms, including a transforming growth factor beta (TGFβ)-driven and LRRC15+ signature associated with immunotherapy resistance. Together, these results demonstrate that radio-theranostic targeting of LRRC15 with DUNP19 is a compelling precision medicine platform for image-guided diagnosis, eradication, and reprogramming of LRRC15+ tumor tissue that drives immuno-resistance and aggressive disease. SIGNIFICANCE: We introduce a pioneering LRRC15-guided radio-theranostic approach integrating clinical imaging and radioimmunotherapy. Our strategy utilizes a mAb, DUNP19, to target LRRC15-expressing cancer cells and fibroblasts, demonstrating significant tumor reduction, prolonged survival, and reversal of TGFβ-driven treatment resistance. This approach offers a promising strategy for improving outcomes in aggressive cancers.


  • Open Access

    Data from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently available noninvasive prostate cancer biomarkers to monitor AR activity are discordant with downstream AR pathway activity. External beam radiotherapy (EBRT) remains a common treatment for all stages of prostate cancer, and DNA damage induced by EBRT upregulates AR pathway activity to promote therapeutic resistance. [89Zr]11B6-PET is a novel modality targeting prostate-specific protein human kallikrein 2 (hK2), which is a surrogate biomarker for AR activity. Here, we studied whether [89Zr]11B6-PET can accurately assess EBRT-induced AR activity.Genetic and human prostate cancer mouse models received EBRT (2–50 Gy) and treatment response was monitored by [89Zr]11B6-PET/CT. Radiotracer uptake and expression of AR and AR target genes was quantified in resected tissue.EBRT increased AR pathway activity and [89Zr]11B6 uptake in LNCaP-AR and 22RV1 tumors. EBRT increased prostate-specific [89Zr]11B6 uptake in prostate cancer–bearing mice (Hi-Myc x Pb_KLK2) with no significant changes in uptake in healthy (Pb_KLK2) mice, and this correlated with hK2 protein levels.Implications:hK2 expression in prostate cancer tissue is a proxy of EBRT-induced AR activity that can noninvasively be detected using [89Zr]11B6-PET; further clinical evaluation of hK2-PET for monitoring response and development of resistance to EBRT in real time is warranted.

  • Open Access

    Data from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently available noninvasive prostate cancer biomarkers to monitor AR activity are discordant with downstream AR pathway activity. External beam radiotherapy (EBRT) remains a common treatment for all stages of prostate cancer, and DNA damage induced by EBRT upregulates AR pathway activity to promote therapeutic resistance. [89Zr]11B6-PET is a novel modality targeting prostate-specific protein human kallikrein 2 (hK2), which is a surrogate biomarker for AR activity. Here, we studied whether [89Zr]11B6-PET can accurately assess EBRT-induced AR activity.Genetic and human prostate cancer mouse models received EBRT (2–50 Gy) and treatment response was monitored by [89Zr]11B6-PET/CT. Radiotracer uptake and expression of AR and AR target genes was quantified in resected tissue.EBRT increased AR pathway activity and [89Zr]11B6 uptake in LNCaP-AR and 22RV1 tumors. EBRT increased prostate-specific [89Zr]11B6 uptake in prostate cancer–bearing mice (Hi-Myc x Pb_KLK2) with no significant changes in uptake in healthy (Pb_KLK2) mice, and this correlated with hK2 protein levels.Implications:hK2 expression in prostate cancer tissue is a proxy of EBRT-induced AR activity that can noninvasively be detected using [89Zr]11B6-PET; further clinical evaluation of hK2-PET for monitoring response and development of resistance to EBRT in real time is warranted.

  • Open Access

    Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.

  • Open Access

    Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.

  • Open Access

    Supplementary Figures 1 and 2 from Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response

    by Claire M. Storey, Mohamed Altai, Mesude Bicak, Darren R. Veach, Katharina Lückerath, Gabriel Adrian, Michael R. McDevitt, Teja Kalidindi, Julie E. Park, Ken Herrmann, et al.

    S1. Hierarchical clustering based on Euclidean distance of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.S2. Multi-dimensional scaling plot of RNA-seq data demonstrates separation of EBRT-treated (B1-3) and untreated (C1-3) samples.